Core Insights - Jiangsu Kangyuan Pharmaceutical Co., Ltd. has announced the inclusion of its unique products, including Wenyang Jiedu Granules and Yunu Decoction, in the National Medical Insurance Directory for 2025, along with the first generic version of Sumatriptan and Naproxen Sodium Tablets [1][2] Group 1 - The company has a total of 123 products included in the National Medical Insurance Directory for 2025, with 48 classified as Category A and 75 as Category B [2] - The payment scope for the company's unique product, Ginkgo Biloba Diterpene Glycoside Ammonium Injection, has been slightly adjusted, now allowing payment only for hospital stays [1] - The company has also had its non-exclusive product, Posaconazole Enteric-Coated Tablets, have payment restrictions lifted, and several new products have been approved for inclusion in the 2025 directory [1][2] Group 2 - The addition of new drug varieties to the National Medical Insurance Directory is expected to drive growth in market promotion and sales for the company, enhancing its research and development innovation and brand influence [2] - The impact of these changes on the company's short-term performance is currently difficult to estimate [2]

Core Viewpoint - Zhongguancun (000931.SZ) announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., has received an acceptance notice from the National Medical Products Administration for the marketing authorization application of Sitagliptin Metformin Tablets (II) [1] Group 1 - Duoduo Pharmaceutical's Sitagliptin Metformin Tablets (II) contain 50mg of Sitagliptin (as Sitagliptin phosphate) and 850mg of Metformin hydrochloride per tablet [1] - The product was initiated for development in 2023 and is indicated for use in combination with diet and exercise to treat type 2 diabetes patients whose blood sugar remains poorly controlled on Metformin monotherapy or who are currently receiving both treatments [1]

Core Viewpoint - The company Zhongguancun (000931) has received acceptance for the marketing authorization application of its drug, Sitagliptin Metformin Tablets, from the National Medical Products Administration, indicating a significant step in expanding its product portfolio in the diabetes treatment market [1] Company Summary - Zhongguancun's subsidiary, Duoduo Pharmaceutical Co., Ltd., has recently received the acceptance notice for the marketing authorization application of Sitagliptin Metformin Tablets [1] - The drug is indicated for the treatment of type 2 diabetes patients who have inadequate blood sugar control with metformin monotherapy or are currently receiving a combination of both treatments [1] Industry Summary - The acceptance of the drug application highlights the ongoing demand and market potential for diabetes medications, particularly for combination therapies that enhance blood sugar control [1] - The drug contains 50mg of Sitagliptin and 850mg of Metformin per tablet, which aligns with current treatment protocols for managing type 2 diabetes [1]

Core Viewpoint - The announcement indicates that Duoduo Pharmaceutical, a subsidiary of Zhongguancun, has received an acceptance notice from the National Medical Products Administration for the marketing authorization application of Sitagliptin Metformin Tablets (II) [1] Group 1: Product Details - The drug is formulated to contain 50mg of Sitagliptin (as Sitagliptin phosphate) and 850mg of Metformin hydrochloride per tablet [1] - It is indicated for type 2 diabetes patients whose blood sugar is not adequately controlled by Metformin monotherapy or who are currently receiving a combination of both medications [1] Group 2: Financial Implications - As of the date of the announcement, the total research and development expenses for this project have reached 6.8755 million yuan [1] - If the drug is successfully approved, it is expected to enhance the market competitiveness of the company's antidiabetic products and positively impact the company's operating performance [1]